Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
About
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
This Notice of Funding Opportunity (NOFO) supports researchers and institutions developing innovative approaches to drug repositioning and combination therapies for Alzheimer's Disease and Related Dementias (AD/ADRD). The grant funds preclinical research using mouse models to test existing drugs—currently approved for other conditions—alongside investigational drug candidates at various stages of development. Applicants can also propose combination studies pairing pharmacologic interventions with non-pharmacologic approaches to generate robust translational evidence. This initiative is ideal for research teams at universities, medical centers, and eligible organizations seeking to establish proof-of-concept for repurposable drugs that could accelerate AD/ADRD treatment and prevention strategies. By funding rigorous preclinical testing before human trials, this program bridges the critical gap between basic discovery and clinical application, enabling rational drug development decisions that could significantly impact millions affected by dementia. Researchers with expertise in bioinformatics, neuroscience, pharmacology, and translational research should consider applying to advance this important therapeutic area.
Funding Facts
● Applications openDeadline
May 7, 2028
Award Amount
Up to $1M
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $1M
Deadline
2028-05-07
Grant Type
federal
Application Cycle
Annual (Deadline: May 7, 2028)
Best For
Academic institutions, HBCUs, minority-serving institutions, research centers, and eligible organizations with expertise in preclinical neuroscience, drug development, and translational bioinformatics
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)?
Eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Indian/Native American Tribal Governments, Faith-based or Community-based Organizations, and Eligible Agencies of the Federal Government. For complete and current eligibility requirements, consult the official NOFO on the funding agency's website.
How much funding does Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) provide?
Funding ranges from no specified minimum up to $1,000,000. The exact amount awarded may vary based on project scope, institution type, and reviewer recommendations. Check the official funding opportunity announcement for current budget guidelines and any funding adjustments for the application cycle.
How do I apply for Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)?
Applications are submitted through the funding agency's grants portal, typically using standardized research proposal formats. You will need to develop a detailed research plan describing your preclinical mouse model studies, drug selection rationale, and expected translational outcomes. Visit the official NOFO webpage for specific submission instructions, required forms, application deadlines, and agency-specific guidance on proposal preparation.
What can Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) funding be used for?
Funding supports preclinical research including rigorous testing of existing drugs and investigational drug candidates in mouse models, evaluation of drug combinations with non-pharmacologic interventions, bioinformatics analysis, and development of robust translational evidence for AD/ADRD therapies. Clinical trials in human subjects are not permitted under this mechanism. Costs typically cover personnel, equipment, supplies, and other direct research expenses as outlined in the grant guidelines.
Last updated: July 5, 2026